Total Funding
76
36
Total FundingSeed raised
Growth Score
-7 pts
Heat Score
-10 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
431467
Apofore is a developer of novel therapeutics for diabetes.
- Patrick Tso: Founder
Christopher K. Mirabelli: President and DirectorPast Role: LeukoSite, Chairman of the Board and Chief Executive Officer
About the Company
Apofore is developing novel therapeutics for Type 2 diabetes based on the naturally occurring protein, Apolipoprotein A-IV (apo A-IV). The company’s approach is based on the discovery by its scientific founder Patrick Tso, PhD, at the University of Cincinnati, of apo A-IV as an important regulator of insulin secretion and glucose homeostasis.
Recombinant apo A-IV, the company’s lead therapeutic is in preclinical development.
